About Shire-Nps Pharmaceuticals (NASDAQ:NPSP)
NPS Pharmaceuticals, Inc. (NPS) is a biopharmaceutical company focused on delivering therapies that transform the lives of patients with rare diseases. The Company’s primary product Gattex 0.05 mg/kg/d (teduglutide [rDNA origin]) for injection, for subcutaneous use was approved the United States Food and Drug Administration (FDA) for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. The Company’s second principal product, Natpara (recombinant human parathyroid hormone 1-84 [rDNA origin] injection, has been developed for hypoparathyroidism, a rare multidimensional disorder characterized by deficient or absent parathyroid hormone (PTH). The Company has collaborations or royalty agreements with Amgen, Janssen, GlaxoSmithKline and Kyowa Hakko Kirin.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
SectorBio Therapeutic Drugs
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-5.98%
Return on Assets-2.77%
Shire-Nps Pharmaceuticals (NASDAQ:NPSP) Frequently Asked Questions
What is Shire-Nps Pharmaceuticals' stock symbol?
Shire-Nps Pharmaceuticals trades on the NASDAQ under the ticker symbol "NPSP."
How were Shire-Nps Pharmaceuticals' earnings last quarter?
Shire-Nps Pharmaceuticals Inc (NASDAQ:NPSP) announced its quarterly earnings results on Wednesday, February, 18th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.06 by $0.08. The biopharmaceutical company had revenue of $66.70 million for the quarter, compared to the consensus estimate of $69.30 million. Shire-Nps Pharmaceuticals had a negative net margin of 2.96% and a negative return on equity of 5.98%. View Shire-Nps Pharmaceuticals' Earnings History.
Who are some of Shire-Nps Pharmaceuticals' key competitors?
Some companies that are related to Shire-Nps Pharmaceuticals include Exelixis (EXEL), bluebird bio (BLUE), Juno Therapeutics (JUNO), Neurocrine Biosciences (NBIX), Bioverativ (BIVV), TESARO (TSRO), Beigene (BGNE), Sarepta Therapeutics (SRPT), Auspex Pharmaceuticals (ASPX), AveXis (AVXS), GW Pharmaceuticals PLC- (GWPH), Clovis Oncology (CLVS), Agios Pharmaceuticals (AGIO), Halozyme Therapeutics (HALO), Spark Therapeutics (ONCE), Loxo Oncology (LOXO), Insmed (INSM) and Array BioPharma (ARRY).
How do I buy Shire-Nps Pharmaceuticals stock?
Shares of Shire-Nps Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How big of a company is Shire-Nps Pharmaceuticals?
Shire-Nps Pharmaceuticals has a market capitalization of $4.99 billion.
How can I contact Shire-Nps Pharmaceuticals?
Shire-Nps Pharmaceuticals' mailing address is 550 Hills Dr, BEDMINSTER, NJ 07921-1537, United States. The biopharmaceutical company can be reached via phone at +1-908-4505300.
MarketBeat Community Rating for Shire-Nps Pharmaceuticals (NPSP)MarketBeat's community ratings are surveys of what our community members think about Shire-Nps Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Shire-Nps Pharmaceuticals (NASDAQ:NPSP) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Shire-Nps Pharmaceuticals (NASDAQ:NPSP) Earnings History and Estimates Chart
Shire-Nps Pharmaceuticals (NASDAQ NPSP) Earnings History by Quarter
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/18/2015||Q414||$0.06||($0.02)||$69.30 million||$66.70 million||View||N/A|
|11/10/2014||Q314||$0.01||($0.02)||$59.50 million||$57.20 million||View||N/A|
|8/6/2014||Q214||($0.01)||$0.02||$53.06 million||$56.10 million||View||Listen|
|5/8/2014||Q114||($0.04)||($0.06)||$48.30 million||$44.04 million||View||Listen|
|2/18/2014||Q413||$0.02||$0.07||$44.22 million||$54.45 million||View||Listen|
|8/8/2013||Q2 2013||($0.07)||($0.13)||$31.62 million||$36.50 million||View||Listen|
|5/9/2013||Q1 2013||($0.13)||($0.09)||$27.56 million||$25.43 million||View||Listen|
|2/21/2013||Q4 2012||($0.09)||($0.14)||$28.93 million||$27.10 million||View||Listen|
|11/9/2012||Q312||($0.16)||($0.04)||$28.18 million||$27.02 million||View||N/A|
Shire-Nps Pharmaceuticals (NASDAQ:NPSP) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Shire-Nps Pharmaceuticals (NASDAQ:NPSP)
No dividend announcements for this company have been tracked by MarketBeat.com
Shire-Nps Pharmaceuticals (NASDAQ NPSP) Insider Trading and Institutional Ownership History
Shire-Nps Pharmaceuticals (NASDAQ NPSP) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|2/10/2015||Susan E Graf||VP||Sell||6,711||$45.87||$307,833.57|| |
|12/17/2014||Joseph J Rogus||SVP||Sell||16,467||$35.00||$576,345.00|| |
|12/17/2014||Luke M Beshar||CFO||Sell||52,258||$35.00||$1,829,030.00|| |
|12/17/2014||Rachel R Selisker||Director||Sell||3,708||$34.59||$128,259.72|| |
|12/8/2014||Rachel R Selisker||Director||Sell||23,157||$34.50||$798,916.50|| |
|11/28/2014||Rachel R Selisker||Director||Sell||11,635||$34.50||$401,407.50|| |
|11/17/2014||Joseph J Rogus||SVP||Sell||26,782||$30.00||$803,460.00|| |
|11/11/2014||Rachel R Selisker||Director||Sell||15,188||$29.50||$448,046.00|| |
|10/31/2014||Luke M Beshar||CFO||Sell||10,000||$29.00||$290,000.00|| |
|10/27/2014||Luke M Beshar||CFO||Sell||30,635||$26.75||$819,486.25|| |
|2/13/2014||Georges Gemayel||Director||Sell||6,188||$37.70||$233,287.60|| |
|1/8/2014||Luke Beshar||CFO||Sell||31,588||$35.01||$1,105,895.88|| |
|12/26/2013||Luke Beshar||CFO||Sell||37,874||$30.02||$1,136,977.48|| |
|12/23/2013||James Groninger||Director||Sell||3,000||$29.50||$88,500.00|| |
|12/18/2013||Ed Stratemeier||SVP||Sell||205,432||$25.13||$5,162,506.16|| |
|9/20/2013||Luke Beshar||CFO||Sell||50,000||$30.26||$1,513,000.00|| |
|9/16/2013||Joseph Rogus||VP||Sell||25,312||$28.11||$711,520.32|| |
|9/16/2013||Luke Beshar||CFO||Sell||50,000||$27.89||$1,394,500.00|| |
|8/30/2013||Roger Garceau||CMO||Sell||110,000||$25.18||$2,769,800.00|| |
|8/20/2013||James Groninger||Director||Sell||16,900||$23.21||$392,249.00|| |
|5/9/2013||Luke M Beshar||CFO||Sell||45,150||$14.18||$640,227.00|| |
|11/15/2012||Glenn R Melrose||SVP||Buy||11,000||$9.09||$99,990.00|| |
|10/3/2012||Roger Garceau||CMO||Sell||140,625||$9.51||$1,337,343.75|| |
Shire-Nps Pharmaceuticals (NASDAQ NPSP) News Headlines
Shire-Nps Pharmaceuticals (NASDAQ:NPSP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Shire-Nps Pharmaceuticals (NASDAQ:NPSP) Income Statement, Balance Sheet and Cash Flow Statement
Shire-Nps Pharmaceuticals (NASDAQ NPSP) Stock Chart for Tuesday, December, 12, 2017